Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC
- PMID: 32674211
Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC
Abstract
Tivozanib (Fotivda) significantly improved progression-free survival (PFS), compared with sorafenib (Nexavar), in patients with highly relapsed or refractory metastatic renal cell carcinoma (RCC), according to results from the phase 3 TIVO-3 trial presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.
MeSH terms
Substances
LinkOut - more resources
Medical